贝伐珠单抗联合同步放化疗在局部进展期宫颈癌患者中的应用效果  

Application effects of Bevacizumab combined with concurrent chemoradiotherapy in patients with locally advanced cervical cancer

作　　者：林布雷 周原[2] LIN Bulei;ZHOU Yuan(Tumor Radiotherapy Department,The First Affiliated Hospital of Xiamen University,Xiamen 361000 Fujian,China;Radiotherapy Department,The First Affiliated Hospital of Xiamen University,Xiamen 361000 Fujian,China)

机构地区：[1]厦门大学附属第一医院肿瘤放疗科,福建厦门361000 [2]厦门大学附属第一医院放射治疗科,福建厦门361000

出　　处：《中国民康医学》2023年第10期72-75,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察贝伐珠单抗联合同步放化疗在局部进展期宫颈癌(LACC)患者中的应用效果。方法:回顾性分析2019年6月至2021年5月该院收治的120例LACC患者的临床资料,按照治疗方案不同将其分为对照组和观察组各60例。对照组给予同步放化疗,观察组在对照组基础上联合贝伐珠单抗治疗。比较两组客观缓解率、治疗前后血清肿瘤标志物指标[癌胚抗原(CEA)、糖类抗原(CA)125、鳞癌相关抗原(SCC)]水平、T细胞亚群指标(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))水平及治疗期间不良反应发生率。结果:治疗后,观察组客观缓解率为80.00%(48/60),高于对照组的55.00%(33/60),差异有统计学意义(P<0.05);治疗后,观察组血清CEA、CA125、SCC水平均低于对照组,差异有统计学意义(P<0.05);观察组CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)水平均高于对照组,CD8^(+)水平低于对照组,差异有统计学意义(P<0.05);两组骨髓抑制、胃肠道反应、肝肾功能异常、脱发、放射性肠炎、放射性膀胱炎等不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:贝伐珠单抗联合同步放化疗应用于LACC患者可提高客观缓解率,降低肿瘤标志物指标水平,改善T细胞亚群指标水平,效果优于单纯同步放化疗。Objective:To observe application effects of Bevacizumab combined with concurrent chemoradiotherapy in patients with locally advanced cervical cancer(LACC).Methods:The clinical data of 120 patients with LACC admitted to the hospital from June 2019 to May 2021 were retrospectively analyzed.According to different treatment plans,they were divided into control group and observation group,60 cases in each group.The control group was given concurrent chemoradiotherapy,while the observation group was treated with Bevacizumab on the basis of that of the control group.The objective remission rate,the levels of tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen(CA)125,squamous cell carcinoma associated antigen(SCC)],he T cell subset levels(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+))before and after the treatment,and the incidence of adverse reactions during the treatment were compared between the two groups.Results:After the treatment,the objective remission rate of the observation group was 80.00%(48/60),which was higher than 55.00%(33/60)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CEA,CA125 and SCC in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,the level of CD8^(+)was lower than that in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions such as bone marrow suppression,gastrointestinal reactions,liver and kidney dysfunction,alopecia,radiation enteritis,and radiation cystitis between the two groups(P>0.05).Conclusions:Bevacizumab combined with concurrent chemoradiotherapy for the LACC patients can improve the objective response rate,reduce the levels of tumor markers,and improve the levels of T cell subsets.Moreover,it is superior to single concu

关 键 词：贝伐珠单抗 同步放化疗 局部进展期宫颈癌 肿瘤标志物 T细胞亚群 不良反应 

分 类 号：R737.33[医药卫生—肿瘤]